{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:28:15Z","timestamp":1774031295126,"version":"3.50.1"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00314","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T05:50:01Z","timestamp":1556085001000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Oligonucleotides\u2014A Novel Promising Therapeutic Option for IBD"],"prefix":"10.3389","volume":"10","author":[{"given":"Patrizio","family":"Scarozza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus F.","family":"Neurath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2174\/0929867054864859","article-title":"Antisense oligonucleotides: the state of the art","volume":"12","author":"Aboul-Fadl","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/ecco-jcc\/jjw103","article-title":"Clinical effects of a topically applied Toll-like receptor 9 agonist in active moderate-to-severe Ulcerative Colitis","volume":"10","author":"Atreya","year":"2016","journal-title":"J. Crohn Colitis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","article-title":"Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease","volume":"3","author":"Atreya","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.dld.2018.06.010","article-title":"Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis","volume":"50","author":"Atreya","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40259-018-0286-1","article-title":"Oligonucleotide-based therapies for inflammatory bowel disease","volume":"32","author":"Bevivino","year":"2018","journal-title":"BioDrugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1053\/j.gastro.2006.09.016","article-title":"Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-\u03b21\u2013mediated suppression of colitis","volume":"131","author":"Boirivant","year":"2006","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1053\/gast.2001.29568","article-title":"Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1\/Yit adoptive transfer model of Crohn's disease in mice","volume":"121","author":"Burns","year":"2001","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev.med.55.091902.104408","article-title":"Progress in antisense technology","volume":"55","author":"Crooke","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ecco-jcc\/jjv133","article-title":"Development of fibrosis in acute and longstanding ulcerative colitis","volume":"9","author":"de Bruyn","year":"2015","journal-title":"J. Crohn Colitis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1007\/s10620-016-4276-1","article-title":"Ameliorating active ulcerative colitis via an orally available toll-like receptor-9 modifier: a prospective open-label, multicenter phase II trial","volume":"61","author":"Dotan","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"B11","unstructured":"Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1053\/j.gastro.2017.08.035","article-title":"Effects of mongersen (GED-0301) on endoscopic and clinical outcomes in patients with active Crohn's disease","volume":"154","author":"Feagan","year":"2018","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2174\/138945011796818225","article-title":"Biological therapy for ulcerative colitis: what is after anti-TNF","volume":"12","author":"Fiorino","year":"2011","journal-title":"Current Drug Targets"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1172\/JCI19836","article-title":"Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis","volume":"113","author":"Fuss","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B15","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.157.3.1261","article-title":"Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5","volume":"157","author":"Fuss","year":"1996","journal-title":"J. Immunol."},{"key":"B16","first-page":"1401","article-title":"Alicaforsen. Isis pharmaceuticals","volume":"2","author":"Gewirtz","year":"2001","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10620-017-4892-4","article-title":"Old and new lymphocyte players in inflammatory bowel disease","volume":"63","author":"Giuffrida","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"B18","first-page":"1173","article-title":"Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)","volume":"282","author":"Glover","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1046\/j.1365-2249.1999.00985.x","article-title":"Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)","volume":"117","author":"Hamamoto","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nri2476","article-title":"GATA3 and the T-cell lineage: essential functions before and after Thelper-2-cell differentiation","volume":"9","author":"Ho","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/gut.36.5.724","article-title":"Adhesion molecules in inflammatory bowel disease","volume":"36","author":"Jones","year":"1995","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1172\/JCI22996","article-title":"Toll-like receptor 9-induced type I IFN protects mice from experimental colitis","volume":"115","author":"Katakura","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1411776","article-title":"Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme","volume":"372","author":"Krug","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-230X-14-79","article-title":"Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients","volume":"14","author":"Kuznetsov","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2003.08.027","article-title":"A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B","volume":"125","author":"Lawrance","year":"2003","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ncb1500","article-title":"Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells","volume":"8","author":"Lee","year":"2006","journal-title":"Nat. Cell. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4049\/jimmunol.1601416","article-title":"TLR9 regulates the NF-\u03baB-NLRP3-IL-1\u03b2 pathway negatively in Salmonella-induced NKG2D-mediated intestinal inflammation","volume":"199","author":"Li","year":"2017","journal-title":"J. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"European Crohn's and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1126\/science.1106442","article-title":"Immunity, inflammation, and allergy in the gut","volume":"307","author":"MacDonald","year":"2005","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1053\/j.gastro.2011.02.047","article-title":"Regulation of homeostasis and inflammation in the intestine","volume":"140","author":"MacDonald","year":"2011","journal-title":"Gastroenterology"},{"key":"B34","first-page":"447","article-title":"A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis","volume":"29","author":"Maksymowych","year":"2002","journal-title":"J. Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07853890.2018.1490025","article-title":"Inflammatory bowel disease: new therapies from antisense oligonucleotides","volume":"16","author":"Marafini","year":"2018","journal-title":"Ann. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/10611860902839502","article-title":"Colonic treatments and targets: issues and opportunities","volume":"5","author":"McConnell","year":"2009","journal-title":"J. Drug Targeting"},{"key":"B37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2036.2004.01863.x","article-title":"An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis","volume":"19","author":"Miner","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1365-2036.2006.02837.x","article-title":"Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial","volume":"23","author":"Miner","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease","volume":"20","author":"Monteleone","year":"2012","journal-title":"Mol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1172\/JCI12821","article-title":"Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease","volume":"108","author":"Monteleone","year":"2001","journal-title":"J. Clin. Investig."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/nejmc1504845","article-title":"Mongersen, an oral Smad7 antisense oligonucleotide, and Crohn's disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40265-013-0176-2","article-title":"T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects","volume":"74","author":"Mosli","year":"2014","journal-title":"Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1365-2249.2000.01183.x","article-title":"Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis","volume":"120","author":"Murano","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ibd.23019","article-title":"Topical treatment with the Toll like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity","volume":"19","author":"Musch","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/gutjnl-2013-305947","article-title":"IL-9 and its receptor are predominantly involved in the pathogenesis of UC","volume":"64","author":"Nalleweg","year":"2015","journal-title":"Gut"},{"key":"B46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm0996-998","article-title":"Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice","volume":"2","author":"Neurath","year":"1996","journal-title":"Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1442-200X.2009.03019.x","article-title":"Increased mucosal expression of GATA-3 and STAT-4 in pediatric ulcerative colitis","volume":"52","author":"Ohtani","year":"2010","journal-title":"Pediatr. Int."},{"key":"B50","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.gastro.2016.09.005","article-title":"Rectal delivery of a DNAzyme that specifically blocks the transcription factor GATA3 reduces colitis in mice","volume":"152","author":"Popp","year":"2016","journal-title":"Gastroenterology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1084\/jem.183.6.2669","article-title":"A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4 T cells","volume":"183","author":"Powrie","year":"1996","journal-title":"J. Exp. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1053\/gast.2002.32994","article-title":"Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis","volume":"122","author":"Rachmilewitz","year":"2002","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S669","DOI":"10.1093\/ecco-jcc\/jjy059","article-title":"Targeting endothelial ligands: (ICAM-1\/Alicaforsen, MAdCAM-1)","volume":"12","author":"Reinisch","year":"2018","journal-title":"J. Crohn Colitis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn's disease complicated by strictures: a systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/ibd.20501","article-title":"Leukocyte adhesion molecules in animal models of inflammatory bowel disease","volume":"14","author":"Rivera-Nieves","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Translat. Gastroenterol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000449077","article-title":"Leukocyte anti-trafficking strategies: current status and future directions","volume":"35","author":"Sands","year":"2017","journal-title":"Dig. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1053\/gast.2001.24015","article-title":"Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease","volume":"120","author":"Schreiber","year":"2001","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1172\/JCI30587","article-title":"The fundamental basis of inflammatory bowel disease","volume":"117","author":"Strober","year":"2007","journal-title":"J. Clin. Invest."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0158967","DOI":"10.1371\/journal.pone.0158967","article-title":"Pivotal role of carbohydrate sulfotransferase 15 in fibrosis and mucosal healing in mouse colitis","volume":"11","author":"Suzuki","year":"2016","journal-title":"PLoS ONE"},{"key":"B62","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/ecco-jcc\/jjw143","article-title":"Phase 1 clinical study of siRNA targeting carbohydrate sulphotransferase 15 in Crohn's disease patients with active mucosal lesions","volume":"11","author":"Suzuki","year":"2017","journal-title":"J Crohn Colitis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/ecco-jcc\/jjw143","article-title":"Phase 1 clinical study of siRNA targeting carbohydrate sulphotransferase 15 in Crohn's disease patients with active mucosal lesions","volume":"11","author":"Suzuki","year":"2017","journal-title":"J. Crohns Colitis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"191","DOI":"10.21037\/atm.2017.03.65","article-title":"New endoscopic approach of anti-fibrotic therapy for inflammatory bowel disease","volume":"5","author":"Suzuki","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/003655299750026065","article-title":"Health-related quality of life after ileal J-pouch-anal anastomosis for ulcerative colitis: long-term results","volume":"34","author":"Tiainen","year":"1999","journal-title":"Scand. J. Gastroenterol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1046\/j.1365-2249.2000.01296.x","article-title":"Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease","volume":"121","author":"Vainer","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1136\/gut.2003.036160","article-title":"A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis","volume":"53","author":"van Deventer","year":"2004","journal-title":"Gut"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/j.1365-2036.2006.02910.x","article-title":"A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis","volume":"23","author":"van Deventer","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/apt.12369","article-title":"Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis","volume":"38","author":"Vegter","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.it.2014.04.002","article-title":"GATA3: a master of many trades in immune regulation","volume":"35","author":"Wan","year":"2014","journal-title":"Trends Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00281-016-0603-z","article-title":"Th9 cells in inflammatory bowel diseases","volume":"39","author":"Weigmann","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"14669","DOI":"10.1111\/apt.14669","article-title":"Review article: novel oral-targeted therapies in inflammatory bowel disease","volume":"19","author":"White","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cgh.2006.11.001","article-title":"A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease","volume":"5","author":"Yacyshyn","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1046\/j.1365-2036.2002.01341.x","article-title":"Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease","volume":"16","author":"Yacyshyn","year":"","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0016-5085(98)70418-4","article-title":"A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease","volume":"114","author":"Yacyshyn","year":"1998","journal-title":"Gastroenterology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/gut.51.1.30","article-title":"Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease","volume":"51","author":"Yacyshyn","year":"","journal-title":"Gut"},{"key":"B77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","article-title":"30 years of NF-\u03baB: a blossoming of relevance to human pathobiology","volume":"12","author":"Zhang","year":"2017","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/apt.12051","article-title":"A phase 1 open-label trial shows that Smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease","volume":"36","author":"Zorzi","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/MIB.0000000000001067","article-title":"Novel insights into the mechanisms of gut homing and antiadhesion therapies in inflammatory bowel diseases","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00314\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:57:41Z","timestamp":1694822261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00314\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":79,"alternative-id":["10.3389\/fphar.2019.00314"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00314","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"article-number":"314"}}